Carmine N. Stengone sold $114k of CTNM
CEO and President at Contineum Therapeutics, Inc.. 7,100 shares at an average of $16.02, traded Feb 24, 2026, filed Feb 26, 2026.
Score components
- +25RoleCEO
- +10Trade size$114k at market
- +10Share of holdings soldSold 37% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.5%, 3m -15.7%, 6m +9.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-005892, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | MOption exercise Class A Common Stock10b5-1 | +4,400 | $1.26 | $5,544 | 19,354 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -4,400 | $16.02 | $70k | 14,954 | Feb 26, 2026 |
| Feb 25, 2026 | MOption exercise Class A Common Stock10b5-1 | +2,700 | $1.26 | $3,402 | 17,654 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,700 | $16.02 | $43k | 14,954 | Feb 26, 2026 |
| Feb 24, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,400 | $0.00 | $0 | 123,617 | Feb 26, 2026 |
| Feb 25, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -2,700 | $0.00 | $0 | 120,917 | Feb 26, 2026 |
Related signals
Other insiders at Contineum Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $41k 2,500 shares | -13% | |
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 0Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $17k 1,040 shares | -1% | |
| 16Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 19Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $595k 37,179 shares | -22% | |
| 26Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $160k 10,000 shares | -37% | |
| 26Weak | Contineum Therapeutics, Inc. | Tim Watkins CMO & Head of Development | $174k 10,833 shares | -55% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $56k 4,170 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.